About US
Contact us
-
Otsuka's Abilify leads Medicaid spending, report finds, with Gilead's hep C meds close behindAmid a period of intense drug pricing scrutiny, data are out on the costliest drugs to Medicaid, with some of pharma's biggest names among the highest-ranking brands. It's a tale of the Medicaid popul2016/8/2
-
Lymphoma trial failure endangers Roche's Gazyva growth plans as Rituxan biosims loomRoche’s Gazyva fell short in a late-stage lymphoma trial, jeopardizing the company’s expansion plans for the Rituxan follow-up. The newer med failed to best gold-standard Rituxan in previously untreat2016/8/1
-
Revlimid snags MCL nod in Europe to take on J&J's ImbruvicaCelgene blood cancer giant Revlimid has picked up another European approval. But as the company gears up to launch the med in its new indication, it’s already got a familiar foe waiting to receive it.2016/8/1
-
GSK and Janssen sign licence agreement for CNTO 7160 asthma treatment worldwideBritish pharmaceutical company GlaxoSmithKline (GSK) has entered into an exclusive, worldwide licence agreement with Janssen Sciences Ireland for CNTO 7160 to treat patients with severe asthma. CNTO2016/7/29
-
IBM team develops new lab-on-a-chip technology for physicians to detect cancerScientists from IBM Research have developed a new lab-on-a-chip technology that can be used to separate biological particles at the nanoscale, thereby allowing physicians to detect diseases such as ca2016/7/29
-
Shire’s SHP626 gets FDA Fast Track designation for NASH with liver fibrosisIrish biopharmaceutical company Shire has been granted the US Food and Drug Administration (FDA) Fast Track designation for SHP626 (volixibat) to treat non-alcoholic steatohepatitis (NASH) with liver2016/7/28
-
Chinese company Fosun acquires majority stake in Gland Pharma for $1.26bnChinese international conglomerate and investment company Fosun Group will acquire a majority stake of approximately 86% within Indian pharmaceutical company Gland Pharma for a value of up to $1.26bn.2016/7/28
-
Mylan and Biocon receive MAA review acceptance from EMA for PegfilgrastimUK-based pharmaceutical company Mylan and Indian biopharmaceutical company Biocon have received the European Medicines Agency (EMA) acceptance for review of Mylan's Marketing Authorisation Application2016/7/27
-
EMA CHMP receives positive opinion for Eisai’s combination treatment for RCCJapanese-based Eisai has received a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) on lenvatinib mesylate in combination with everoli2016/7/27
-
Suicide link has FDA staffers iffy on Valeant's brodalumabValeant ($VRX) has been touting the potential of psoriasis candidate brodalumab to help the struggling company stage its turnaround. But ahead of an advisory committee meeting to assess the drug, FDA2016/7/26